Valentina Zoboli | Public Health | Best Review Paper Award

Best Review Paper Award

Valentina Zoboli — Fondazione IRCCS Policlinico San Matteo

Valentina Zoboli
Affiliation Fondazione IRCCS Policlinico San Matteo
Country Italy
Scopus ID 58178883000
Documents 3
Citations 9
h-index 1
Subject Area Public Health
Event The Scientist Global Awards
ORCID 0009-0005-2716-7366

The Best Review Paper Award recognizes scholarly excellence in synthesizing existing scientific knowledge, identifying research gaps, and advancing evidence-based understanding within a specialized field. This article presents an academic overview of Valentina Zoboli of Fondazione IRCCS Policlinico San Matteo, Italy, highlighting research activities, publication contributions, and scholarly impact relevant to consideration for recognition at The Scientist Global Awards.[1]

Abstract

This article examines the academic profile and research contributions of Valentina Zoboli within the field of Public Health. The assessment focuses on scholarly productivity, evidence synthesis activities, publication quality, and the broader significance of review-oriented research outputs. Review papers play a critical role in consolidating scientific evidence, guiding future investigations, and supporting evidence-based decision-making across healthcare systems. The presented profile demonstrates engagement with scientific dissemination and interdisciplinary knowledge development, factors commonly considered in review paper award evaluations.[2]

Keywords

Public Health; Review Paper; Scientific Literature; Evidence Synthesis; Research Evaluation; Scholarly Impact; Academic Recognition; Health Research; Citation Analysis; Research Excellence.

Introduction

Review articles serve as foundational resources for researchers, clinicians, and policymakers by integrating findings from multiple studies into coherent frameworks. High-quality review papers contribute to scientific advancement through critical evaluation of evidence, identification of emerging trends, and clarification of unresolved research questions. Recognition through a Best Review Paper Award therefore reflects both scholarly rigor and the ability to communicate complex knowledge effectively.[3]

Research Profile

Valentina Zoboli is affiliated with Fondazione IRCCS Policlinico San Matteo, a recognized Italian institution engaged in clinical and biomedical research. Her scholarly activities are represented in the Scopus database under Author ID 58178883000. Available bibliometric indicators report three indexed documents, nine citations, and an h-index of one, reflecting early-stage but measurable research visibility within the academic community.[1]

Research Contributions

Research contributions associated with review-oriented scholarship involve the systematic collection, interpretation, and presentation of scientific evidence. Such work supports clinical practice, public health planning, and future research design. Contributions of this nature frequently include literature evaluation, methodological comparison, evidence mapping, and synthesis of multidisciplinary findings.[4]

Publications

The publication portfolio indexed under the author’s Scopus profile demonstrates participation in peer-reviewed scholarly communication. Review papers and related scientific outputs contribute to the dissemination of consolidated knowledge and facilitate broader understanding of public health challenges and solutions.[1]

Research Impact

Research impact may be evaluated through bibliometric indicators, scholarly visibility, citation activity, and the practical relevance of scientific findings. Citation records indicate that the author’s publications have attracted attention within the academic community. Although bibliometric indicators represent only one aspect of research quality, they provide measurable evidence of engagement and dissemination.[1].

Award Suitability

Eligibility for a Best Review Paper Award is typically based on originality of synthesis, methodological rigor, scientific clarity, relevance to the discipline, and contribution to evidence-based advancement. Valentina Zoboli’s scholarly profile demonstrates characteristics associated with academic review excellence, including engagement with peer-reviewed literature, participation in scientific dissemination, and contributions within the Public Health domain. These attributes support consideration for recognition by The Scientist Global Awards.[5]

Conclusion

Valentina Zoboli represents an emerging contributor to Public Health scholarship through participation in peer-reviewed research and scientific knowledge dissemination. The available bibliometric profile, institutional affiliation, and research engagement collectively illustrate a foundation for scholarly recognition. Within the context of review-based academic achievement, the profile aligns with the objectives of the Best Review Paper Award and highlights the importance of evidence synthesis in advancing scientific understanding.[1]

References

  1. Elsevier. (2026). Scopus author details: Valentina Zoboli, Author ID 58178883000. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=58178883000
  2. Grant, M. J., & Booth, A. (2009). A typology of reviews: An analysis of review types and associated methodologies.
    https://doi.org/10.1111/j.1471-1842.2009.00848.x
  3. Valentina Zoboli. (2026). Human cytomegalovirus-specific T-cell responses and immune-guided strategies as predictors of clinically significant infection in hematopoietic stem cell transplant recipients after letermovir prophylaxis.
    https://pubmed.ncbi.nlm.nih.gov/41501398/
  4. Page, M. J., et al. (2021). PRISMA 2020 statement: An updated guideline for reporting systematic reviews.
    https://doi.org/10.1136/bmj.n71
  5. The Scientist Global Awards. (2026). Award evaluation criteria and academic recognition framework.
    https://thescientists.net/

“`

Hajer Nabli | Public Health | Research Excellence Award

Assist. Prof. Dr. Hajer Nabli | Public Health | Research Excellence Award

Assistant Professor | University of Sousse, ISITCom | Tunisia

Assist. Prof. Dr. Hajer Nabli is a distinguished researcher specializing in cloud computing, blockchain, and AI-driven Internet of Things (AIoT) applications. She has authored multiple high-impact publications, with 128 citations, an h-index of 6, and an i10-index of 4, reflecting her significant contributions to service discovery, cloud service recommendation, and semantic similarity modeling. Her work emphasizes innovative solutions for cloud service personalization, web service composition, and the integration of emerging technologies into pharmaceutical and smart city applications. Collaborating extensively with international scholars, Nabli has advanced practical applications such as quality-aware context monitoring for smart homes and blockchain-enabled supply chain security. Her research demonstrates a strong societal impact, addressing critical challenges in technology adoption, elderly care, and counterfeit drug prevention.

Citation Metrics (Google Scholar)

128
100
80
40
0

Citations

128

h-index

6

i10-index

4

Citations

h-index

i10-index

View Google Scholar Profile View ORCID Profile

Featured Publications

Ilias Karaiskos | Public Health | Best Researcher Award

Dr. Ilias Karaiskos | Public Health | Best Researcher Award

1st Department of Internal Medicine-Infectious Diseases |  Hygeia hospital, Athens | Greece

Dr. Ilias Karaiskos is a distinguished physician and clinical researcher specializing in internal medicine and infectious diseases at the 1st Department of Internal Medicine, Hygeia General Hospital, Athens, Greece. Working under the leadership of Professor H. Giamarellou, he has contributed extensively to the management of complex infections, infection control, and antimicrobial stewardship within one of Greece’s most advanced and internationally accredited healthcare institutions. Dr. Karaiskos’s research focuses on antimicrobial pharmacokinetics, multidrug-resistant pathogens, and optimized antibiotic therapy in critically ill patients. His doctoral work on the pharmacokinetics of colistin significantly influenced global clinical practice, forming part of the International Consensus Guidelines for the Optimal Use of Polymyxins. Recognized by the Hellenic Society for Infectious Diseases with the Best PhD Award (2015), his research has shaped antibiotic dosing strategies that improve patient outcomes and reduce antimicrobial resistance. With over 80 peer-reviewed publications and an h-index of 39, Dr. Karaiskos has amassed more than 5,600 citations through collaborative studies with leading European and global research consortia, including the EUROBACT-2 Study Group, the European Society of Intensive Care Medicine (ESICM), and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). His recent works address the efficacy of novel β-lactamase inhibitors, pharmacokinetics of ceftazidime-avibactam in renal replacement therapy, and strategies for infection control in intensive care settings. Through his clinical leadership, academic collaborations, and evidence-based research, Dr. Karaiskos continues to advance the global fight against antimicrobial resistance, shaping policies and treatment guidelines that enhance the quality and safety of infectious disease management worldwide.

Featured Publications

  1. Tsuji, B. T., Pogue, J. M., Zavascki, A. P., Paul, M., Daikos, G. L., Forrest, A., Karaiskos, I., … (2019). International consensus guidelines for the optimal use of the polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and others. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 39(1), 10–39. Citations: 949

  2. Plachouras, D., Karvanen, M., Friberg, L. E., Papadomichelakis, E., Karaiskos, I., … (2009). Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. Antimicrobial Agents and Chemotherapy, 53(8), 3430–3436. Citations: 637

  3. Gutiérrez-Gutiérrez, B., Salamanca, E., de Cueto, M., Hsueh, P. R., Viale, P., Karaiskos, I., … (2017). Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): A retrospective cohort study. The Lancet Infectious Diseases, 17(7), 726–734. Citations: 545

  4. Karaiskos, I., & Giamarellou, H. (2014). Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: Current and emerging therapeutic approaches. Expert Opinion on Pharmacotherapy, 15(10), 1351–1370. Citations: 435

  5. Karaiskos, I., Lagou, S., Pontikis, K., Rapti, V., & Poulakou, G. (2019). The “old” and the “new” antibiotics for MDR Gram-negative pathogens: For whom, when, and how. Frontiers in Public Health, 7, 151. Citations: 328